| Literature DB >> 26965999 |
Ailin Zhang1, Jiawei Zhang2, Arja Kaipainen1, Jared M Lucas1, Hong Yang3.
Abstract
As one of the most frequently diagnosed cancers in males, the development and progression of prostate cancer remains an open area of research. The role of lncRNAs in prostate cancer is an emerging field of study. In this review, we summarize what is currently known about lncRNAs in prostate cancer while focusing on a few key lncRNAs. PCA3 was the first lncRNA identified in prostate cancer and has been shown to be expressed in a majority of prostate cancer cases. It may act in both an androgen dependent and independent fashion and has clinical utility as a biomarker. Other lncRNAs are known to interact directly with the androgen receptor pathway including PlncRNA-1, HOTAIR, PRNCR1 and PCGEM1. Additionally, lncRNAs have been shown to interfere with tumor suppressors, DNA break repair, transcription and alternate RNA splicing. While only in its infancy, an understanding of the role of lncRNAs in prostate cancer development should present ample opportunities for the discovery of new cancer biomarkers and therapeutic targets.Entities:
Keywords: Androgen receptor; Biomarker; LNCaP
Mesh：
Substances：
Year: 2016 PMID： 26965999 DOI： 10.1016/j.canlet.2016.03.003
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679